Squamous dierentiation of keratinocytes is associated with decreases in E2F-1 mRNA expression and E2F activity, and these processes are disrupted in squamous cell carcinoma cell lines. We now show that E2F-1 mRNA expression is increased in primary squamous cell carcinomas of the skin relative to normal epidermis. To explore the relationship between E2F-1 and squamous dierentiation further, we examined the eect of altering E2F activity in primary human keratinocytes induced to dierentiate. Promoter activity for the proliferationassociated genes, cdc2 and keratin 14, are inhibited during squamous dierentiation. This inhibition can be inhibited by overexpression of E2F-1 in keratinocytes. Overexpression of E2F-1 also suppressed the expression of dierentiation markers (transglutaminase type 1 and keratin 10) in dierentiated keratinocytes. Blocking E2F activity by transfecting proliferating keratinocytes with dominant negative E2F-1 constructs inhibited the expression of cdc2 and E2F-1, but did not induce dierentiation. Furthermore, expression of the dominant negative construct in epithelial carcinoma cell lines and normal keratinocytes decreased expression from the cdc2 promoter. These data indicate that E2F-1 promotes keratinocyte proliferation-speci®c marker genes and suppresses squamous dierentiation-speci®c marker genes. Moreover, these data indicate that targeted disruption of E2F-1 activity may have therapeutic potential for the treatment of squamous carcinomas.
Introduction
A major function of the epidermis is to act as a barrier that inhibits entry of harmful chemicals and pathogens while preventing the loss of body¯uids (Rook et al., 1998) . The integrity of this barrier is maintained by the continuous dierentiation of epidermal keratinocytes. Squamous dierentiation of keratinocytes requires a change in intermediate ®lament (keratin) expression and the commitment of non-proliferative keratinocytes to form a corni®ed cross-linked envelope. This dierentiation programme is a tightly regulated process, characterized by the irreversible growth arrest of keratinocytes and transcriptional downregulation of growth related genes such as E2F-1, p53, keratin 14 and cdk-1 (Lane et al., 1985; Woodworth et al., 1993; Saunders and Jetten, 1994; Jones et al., 1997b; Dahler et al., 1998) . This is followed by the induction of squamous dierentiation-speci®c genes such as transglutaminase type 1 (TG I), keratin 10 and corni®n (Rieger and Franke, 1988; Marvin et al., 1992; Saunders et al., 1993b; Saunders and Jetten, 1994) . Binding of transcription factors to the promoter regions of these genes has been demonstrated to activate or repress their activity (Leask et al., 1991; Casatorres et al., 1994; DiSepio et al., 1995; Welter et al., 1996; Medvedev et al., 1999) . Thus, the regulation of epidermal gene expression is mediated by transcriptional events (Saunders et al., 1993a; Saunders and Jetten, 1994; Arany et al., 1997; Eckert et al., 1997) and results in the characteristic expression of genes required for dierent stages of squamous dierentiation. This programme of dierentiation can be mimicked in-vitro (Saunders et al., 1993a; Saunders and Jetten, 1994; .
Squamous tumours of the skin frequently demonstrate defective control of the dierentiation programme (Lymboussaki et al., 1996; Moll et al., 1997; Hauser et al., 1998) , such as insensitivity to dierentiation inducing stimuli (Jones et al., 1997b) and inappropriate expression of dierentiation-speci®c mRNA in proliferating cells (Dicker et al. submitted) . This deregulation of transcriptional processes may be causally associated with the development of squamous carcinomas, since deliberate activation of E2F in normal keratinocytes leads to growth-inhibitor insensitivity (Jones et al., 1997b) . A better understanding of normal keratinocyte dierentiation may lead to alternate skin tumour therapies that manipulate the deregulated control of dierentiation that is characteristic of squamous tumours. Downregulation of expression of the transcription factor and key cell cycle regulator, E2F, is an early event in normal squamous dierentiation (Saunders et al., 1993b) . There are currently six known members of the E2F family in humans, E2F-1 to E2F-6 (Kaelin et al., 1992; Shan et al., 1992; Helin et al., 1992; Lees et al., 1993; Ivey-Hoyle et al., 1993; Beijersbergen et al., 1994; Ginsberg et al., 1994; Itoh et al., 1995; Buck et al., 1995; Gaubatz et al., 1998; Trimarchi et al., 1998; Cartwright et al., 1998) , which associate with one of two dimerization partners (DP1 and DP2) (Girling et al., 1993; Rogers et al., 1996) to increase the activity of E2F bound to the promoter region of E2F responsive genes. E2F-1 is the best characterized of the family, with evidence implicating it as a key regulator of G1/S phase traverse (Johnson and Schneider-Broussard, 1998; Yee et al., 1998) . The E2F family is in part regulated by binding of pocket proteins such as pRb (Mayol and Grana, 1997) which in turn are regulated by cyclin/cdk complexes. Deregulation or mutations in components of this pathway are seen in most if not all tumours (Weinberg, 1995) . For example, the E7 protein of human papilloma virus (HPV16 E7) is found in the majority of cervical carcinomas (Schwarz et al., 1985) . HPV16 E7 can bind to pRb (Chittenden et al., 1991; Stirdivant et al., 1992) , preventing interaction with E2F proteins (Pagano et al., 1992; Huang et al., 1993) , and selective disruption of the Rb pathway with HPV16 E7 has been reported to inhibit dierentiation (Gilles et al., 1994; Steenbergen et al., 1996; Jones et al., 1997a) .
Recent data concerning the functions of E2F-1 appear contradictory. For instance, E2F-1 has been reported to (i) be oncogenic (Johnson et al., 1994; Pierce et al., 1998) ; (ii) act as a tumour suppressor (Yamasaki et al., 1996) ; (iii) promote apoptosis (Shan and Lee, 1994; Qin et al., 1994) ; (iv) transform cells (Yang and Sladek, 1995; Sladek, 1996) ; or (v) block dierentiation (Wang et al., 1995; Guy et al., 1996) . The most likely explanation for these opposing eects may be attributed to cell type-restricted functions for E2F-1. Such cell type-speci®city highlights the importance of studying E2F action in the context of a speci®c tissue type of biological relevance. In mouse keratinocytes, overexpression of E2F-1 under the proliferation-associated Keratin 5 promoter resulted in hyperkeratosis in the interfollicular epidermis, whilst a decrease in hair follicle number was attributed to an increase in apoptosis in the developing hair (Pierce, et al., 1998) . This suggests that even within the same cell type, E2F-1 function may vary dependent on the dierentiation-speci®c role of the constituent cell type.
A number of studies have suggested an important role for cell cycle proteins, and in particular the pRb pathway, in regulation of keratinocyte dierentiation (Kikuchi et al., 1992; Betz and Pelling, 1995; Lymboussaki, et al., 1996; Harvat et al., 1998) , and both E2F-1 mRNA expression and E2F DNA binding activity have been shown to closely correlate with the dierentiation status of normal keratinocytes (Jones, et al., 1997b) . Interestingly, other E2F family members (E2F-2, 3, 4 or 5) did not appear to be associated with keratinocyte proliferation or dierentiation status (Jones et al., 1997b) .
To extend our previous studies of E2F activity in human keratinocyte function, we were interested in exploring the eect of E2F-1 on the entire dierentiation process. Since this process is at least in part regulated at the level of transcription, we chose to study the eect of overexpressing E2F-1 by transfecting normal keratinocytes with well characterized reporter constructs for both proliferation and dierentiation-speci®c genes. Furthermore, since keratinocyte dierentiation is associated with a marked decrease in E2F DNA binding activity (Jones et al., 1997b) , we wished to examine the eect of inhibiting E2F binding to DNA on keratinocyte proliferation and dierentiation. We were then able to extend the studies of E2F DNA binding inhibition to epithelial tumour cell lines.
Results
Overexpression of E2F-1 inhibits the induction of differentiation markers in normal human keratinocytes treated with differentiation-inducing agents Treatment of primary human keratinocytes cultures with TPA activates protein kinase C and induces dierentiation (Adams and Watt, 1988; Jetten et al., 1989; Saunders et al., 1993a) . The early phase of keratinocyte dierentiation is characterized by the growth arrest of the cells and down regulation of proliferation-associated genes such as E2F-1 and cdc2 (Sharpe et al., 1994; Jones et al., 1997b; Saunders et al., 1998) . Keratinocytes transfected with the E2F-1-responsive cdc2 promoter (Dalton, 1992) linked to the CAT reporter gene (cdc2-CAT) demonstrated a decrease in the activity of the cdc2 promoter in TPA treated cells relative to proliferative cells (Figure 1a ). This correlates with the decrease in cdc2 mRNA expression previously described in keratinocytes treated with TPA (Saunders et al., 1993b) . As well as proliferation-associated genes, undierentiated keratinocytes express the cytokeratin 14 intermediate ®la-ment proteins (Fuchs and Green, 1980) . Keratinocytes transfected with the keratin 14 promoter linked to the CAT reporter gene (K14-CAT) also demonstrated a decrease in activity of the keratin 14 promoter in TPA treated cells relative to proliferative cells (Figure 1b) .
Keratinocyte dierentiation is characterized by the induction of epithelial-speci®c, dierentiation-associated genes such as TGI and corni®n (Marvin et al., 1992; Saunders et al., 1993a) . Keratinocytes transfected with the TG I promoter linked to the luciferase reporter gene (TG I-Luc) demonstrated a 7.5-fold induction of promoter activity when cells were treated Figure 1 E2F-1 transfected into primary human keratinocyte cultures. Human epidermal keratinocytes were transfected with (a) a CAT reporter linked to the cdc2 promoter (cdc2-CAT), (b) a CAT reporter linked to the keratin 14 promoter (K14-CAT), (c) a luciferase reporter linked to the Transglutaminase type I promoter (TG I-Luc) or (d) a luciferase reporter linked to the Keratin 10 promoter (K10-Luc). Each construct was co-transfected with a b actin reporter, to correct for transfection eciency, as well as either the CMV-E2F-1 construct (TPA+E2F-1) or CMV-GFP (Prol and TPA) as a control. After transfection, cells were either maintained in normal growth media (Prol) or maintained in growth media supplemented with 50 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA and TPA+E2F-1) for 24 h to induce dierentiation of the keratinocytes. Data are presented as mean+s.e.m. of triplicate determinations of at least two experiments and are normalized so that the value of proliferating cells is 100 with TPA ( Figure 1c ). This correlates with the sevenfold induction of TGI mRNA expression seen in keratinocytes treated with TPA (Saunders et al., 1993a) . Dierentiation induces a switch in keratin expression pro®le; a decrease in the expression of cytokeratins 5 and 14 is followed by an induction of cytokeratins 1 and 10 (Woodcock- Mitchell et al., 1982) . The Keratin 10 promoter linked to the luciferase reporter gene (K10-Luc), when transfected into normal keratinocytes, is induced eightfold when cells are stimulated to dierentiate with TPA ( Figure 1d ). These data validate the use of these reporter constructs as markers of induction of the dierentiation programme in keratinocytes.
When E2F-1 is overexpressed in keratinocytes, and these cells are induced to dierentiate by the addition of TPA, transcription from the cdc2 and keratin 14 promoters is not down-regulated by TPA, but upregulated relative to proliferating cells ( Figure  1a ,b). These data suggest that (i) active transcription can take place in the presence of excess E2F-1; (ii) expression of E2F-1 can prevent the down-regulation of proliferation markers that normally occurs during TPA-induced dierentiation and (iii) it is unlikely that E2F-1 is causing apoptosis under these conditions. Further, when E2F-1 is overexpressed in keratinocytes, and these cells are induced to dierentiate by the addition of TPA, transcription from the dierentiationspeci®c TG I and Keratin 10 promoters is inhibited (Figure 1c,d) . Therefore, E2F-1 overexpression prevents both the transcriptional downregulation of proliferation markers and the transcriptional induction of dierentiation markers in normal keratinocytes.
Repression of TG I or K10 transcription by overexpressing E2F-1 may be mediated by (i) E2F-1 induced inhibition of the TPA signalling pathway that initiates dierentiation or (ii) E2F-1 induced (directly or indirectly) suppression of expression of these dierentiation markers. Therefore, we initiated experiments to test whether E2F-1 could suppress the transcription of TG I in keratinocytes that were already dierentiated. TGI mRNA is markedly induced 16 h after TPA treatment of keratinocytes ( Figure 2a ). By ®rst treating cells with TPA for 16 h, and then cotransfecting keratinocytes with E2F-1 and the TG ILuc reporter, we demonstrated that TG I promoter activity was suppressed by overexpressing E2F-1 in dierentiated keratinocytes (Figure 2b ). In keratinocytes treated with TPA without the overexpression of E2F-1, expression from the TG I promoter is maintained. These data suggest that in primary human keratinocyte cultures, E2F-1 is able to actively suppress the induction of, or continued activity of, dierentiation markers at a transcriptional level.
Inhibition of E2F DNA binding activity in proliferating keratinocytes inhibits expression of proliferation-associated markers but does not induce differentiation-specific markers
We have previously demonstrated by gel shift analysis that keratinocyte dierentiation is associated with a marked decrease in total E2F binding to DNA (Jones et al., 1997b) . To test the eect of inhibiting E2F activity in primary keratinocyte cultures, and in particular to determine whether a decrease in E2F binding to DNA is sucient to induce keratinocyte dierentiation, competitive inhibitors of E2F DNA binding activity were designed that contained either (i) the DNA binding domain and dimerization domain of E2F-1 (amino acids 116 ± 235); (ii) the DNA binding domain of E2F-1 (amino acids 116 ± 191); or (iii) the dimerization domain of E2F-1 (amino acids 181 ± 235) ( Figure 3a ). These constructs do not contain the cyclin A binding domain, the Rb binding domain or the trans-activation domain of E2F-1. Based on the known functions of these domains, it was predicted that these constructs would be able to bind to E2F DNA binding sites or interact with DP proteins, but would be unable to activate transcription, interact with pocket proteins or be regulated by cyclin A. Each of these constructs contains the E2F-1 nuclear localization sequence.
Transfection of each of these constructs into proliferating primary keratinocyte cultures induced a 1.5 ± 4-fold decrease in cdc-2 promoter activity ( Figure  3b ), suggesting that inhibiting E2F DNA binding leads to a decrease in expression of proliferation-associated genes, although only inhibition observed with the 116 ± 235 construct reached signi®cance (Z=1.76141, P50.05, Mann ± Whitney U test). Therefore the construct which contained both the DNA binding domain and the dimerization domain (116 ± 235) was used in further experiments. E2F-1 mRNA expression is decreased during keratinocyte dierentiation, and the E2F-1 promoter, like the cdc2 promoter, contains two E2F binding sites and is E2F-1-dependent . A 728 bp fragment of the E2F-1 promoter ((728) E2F-1), or the same length fragment with a mutation introduced into the E2F binding sites ((7E2F) E2F-1), in each case linked to the luciferase reporter gene, were transfected into proliferating keratinocytes. A twofold inhibition of expression from the (728)E2F-1 reporter was noted when cells were transfected with the 116 ± 235 construct (Figure 3c ). All reporter activity was lost when the same promoter construct with mutations in the E2F binding domains ((7E2F)E2F) were transfected into cells (Figure 3c ). These data suggest that the E2F-1 promoter is E2F-dependent in keratinocytes and that a construct containing only the E2F-1 DNA binding domain and heterodimerization domain is sucient to decrease the activity of E2F-dependent proliferation markers in keratinocytes (cdc2 and E2F-1).
In contrast to cdc2 or E2F-1 promoter activity, K14 promoter activity was not inhibited by the 116 ± 235 construct (Figure 3d ), instead showing a 2.5-fold induction in activity over proliferative cells. Therefore, the 116 ± 235 construct can suppress expression from proliferation markers with known E2F binding sites, but did not suppress expression from a promoter which is a marker of the undierentiated state in keratinocytes, but which lacks putative E2F binding sites, arguing that inhibition is direct.
We next examined the eect of inhibiting E2F DNA binding on transcription from dierentiation-speci®c reporters. No induction of either the TG I or Keratin 10 promoter could be demonstrated in keratinocytes transfected with the 116 ± 235 construct (Figure 4a and b). From this we were able to conclude that the 116 ± 235 construct inhibits expression of proliferationassociated genes in keratinocytes, but it is not sucient to induce keratinocyte dierentiation-speci®c marker genes. Transfection eciency (approximately 10 ± 20%) in keratinocytes did not allow for any meaningful estimates of the growth rate of these cells (thymidine incorporation) to be made.
Inhibition of E2F DNA binding activity inhibits expression of proliferation-associated genes in epithelial carcinoma cell lines and immortalized keratinocytes Our earlier work (Jones et al., 1997b) demonstrated that E2F DNA binding activity and E2F-1 mRNA expression are substantially increased in the SCC 25 epithelial carcinoma cell line, and E2F activity is not downregulated when cells are treated with dierentiation inducing agents. This suggests that deregulation of E2F DNA binding activity may be associated with (116 ± 235, 116 ± 191, 181 ± 235) were co-transfected with the cdc2-CAT reporter, and with b actin-luciferase to allow correction of transfection eciency. After transfection, cells were maintained in normal growth media for a further 48 h before harvesting for reporter assays. Data are presented as mean+s.e.m. of triplicate determinations of three experiments and are normalized so that the value of proliferating cells is 100. (c) Keratinocytes were co-transfected with a luciferase reporter linked to either 728 bp of the E2F-1 promoter ((728) E2F-1) or the same 728 bp with a mutation in the E2F DNA binding sites ((7E2F) E2F-1), the b actin-CAT to control for transfection eciency, and either VP22-GFP as a control or VP22-116-235 (116 ± 235). After transfection, cells were maintained in normal growth media for a further 48 h before harvesting for reporter assays. Data are presented as mean+s.e.m. of triplicate determinations of two experiments and are normalized so that the value of the ((728) E2F-1) transfected cells is 100. (d) Keratinocytes were co-transfected with the keratin 14 promoter linked to the CAT reporter gene (K14-CAT), the b actinLuciferase reporter and either the VP22-GFP (Prol and TPA) or the VP22-116-235 (116 ± 235) constructs. After transfection, cells were either maintained in normal growth media (Prol and 116 ± 235) or maintained in growth media supplemented with 50 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA) for a further 48 h. Data are presented as mean+s.e.m. of triplicate determinations of three experiments and are normalized so that the value of proliferating cells is 100. *indicates P50.05 Figure 4 Competitive inhibition of E2F DNA binding does not induce dierentiation of normal keratinocytes. Keratinocytes were co-transfected with a luciferase reporter linked to either the (a) Transglutaminase type I promoter (TG I-Luc) or (b) Keratin 10 promoter (K10-Luc), and a b actin-CAT reporter to correct for transfection eciency as well as either the VP22-116-235 construct (116 ± 235) or VP22-GFP (Prol and TPA) as controls. After transfection, cells were either maintained in normal growth media (Prol and 116-235) or maintained in growth media supplemented with 50 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA) for a further 48 h. Data are presented as mean+s.e.m. of triplicate determinations of three experiments and are normalized so that the value of proliferating cells is 100 carcinoma formation in epithelial cells. To further explore the deregulation of E2F-1 in squamous carcinomas, mRNA was isolated from six independent primary squamous cell carcinomas of the skin and the levels of E2F-1 mRNA expression compared to those seen in normal skin. Figure 5 shows that E2F-1 mRNA levels are markedly elevated in squamous cell carcinomas compared to normal epidermis, suggesting either a deregulation of E2F-1 mRNA expression in squamous skin tumours, or a marked increase in the population of proliferative cells in the tumour samples. These data add further evidence for a role of E2F-1 deregulation in skin carcinogenesis, and hence the relevance of manipulating E2F-1 activity as a therapeutic tool in the treatment of this condition.
Transfection of the 116-235 construct into the SCC 25, Cos 1 and HaCaT cell lines led to a signi®cant decrease in expression from the cdc2 promoter (Table  1 ). In Cos 1 cells, where transfection eciency was high (90 ± 95%), transfection of the 116 ± 235 construct induced a decrease in both cdc2 promoter activity and DNA synthesis ( Figure 6 ). However, in KJD1/ SV40 cells and Colo 16 cells the E2F DNA binding inhibitor construct did not induce down-regulation of cdc2 promoter activity (Table 1 ). These data suggest that the 116 ± 235 construct can reduce expression of proliferation markers not only in primary keratinocyte cultures, but also in some but not all epithelial cell lines.
Discussion
This work demonstrates that E2F, and E2F-1 in particular, may play a dual role as both a regulator of proliferation and a suppressor of dierentiation in keratinocytes (Figure 7) . In this study we show that overexpression of E2F-1 in human keratinocytes can inhibit the induction of dierentiation-speci®c genes, and can also suppress the transcription of dierentiation-speci®c genes in previously dierentiated keratinocytes. Treatment of proliferative keratinocytes with TPA induces growth arrest and dierentiation and this is associated with a decrease in E2F DNA binding activity (Jones et al., 1997b) and a decrease in proliferation markers. Overexpression of E2F-1 in dierentiated cells is able to override the downregulation of proliferation markers (cdc2 and K14) and is also able to suppress the subsequent induction of the dierentiation speci®c genes Transglutaminase Type I and keratin 10. The ability of E2F-1 to inhibit dierentiation has been demonstrated in a number of other tissues including blood cells (Guy et al., 1996; Strom et al., 1998) , muscle (Wang et al., 1995 (Wang et al., , 1996 Tiainen et al., 1996) , and neural tissue (Suda et al., 1994; Neuman et al., 1995) , suggesting that E2F-1 may play a role in controlling the normal dierentiation process. However, it was not evident in those studies whether E2F-1 operated simply by maintaining the proliferative state of cells or whether it could also actively participate in the suppression of dierentiation. In this study we provide evidence that E2F-1 maintains the proliferative state of keratinocytes and actively suppresses dierentiation. A recent study reported that deregulated expression of E2F-1 in the mouse epidermis induced hyperplasia and hyperproliferation but did not inhibit terminal dierentiation (Pierce et al., 1998) . However, in this transgenic model, E2F-1 was expressed from the keratin 5 promoter, which is normally only expressed in the basal layer of the epidermis and is`switched o' when cells move into the suprabasal layer. Therefore if cells were able to Figure 5 E2F-1 mRNA expression in normal epidermis and squamous cell carcinomas of the skin. RNA was extracted from six separate excised squamous cell carcinomas from dierent patients, morphologically normal perilesional skin and normal foreskins as described in Materials and methods then subjected to RT ± PCR using E2F-1 speci®c oligonucleotides. Expression levels of b actin mRNA are shown to demonstrate that equivalent amounts of cDNA were used for each sample. All samples of SCC were con®rmed histologically Figure 7 Model for the eects of E2F-1 on keratinocyte dierentiation Figure 6 Cdc2 reporter activity and DNA synthesis in Cos 1 cells transfected with an E2F DNA binding inhibitor. Cos 1 cells were transfected with either VP22-GFP (Prol) or VP22-116-235 (116 ± 235) for 48 h and either (1) tritiated thymidine added for the last 3 h of the assay (DNA Synthesis), or (2) cells were cotransfected with the cdc2-CAT reporter and the b actin-Luc reporter and relative activity assayed (relative cdc2 activity; see Materials and methods). Data are presented as mean+s.e.m. of triplicate determinations of three experiments and are normalized so that the value of proliferating cells is 100 leave the basal layer and switch o the keratin 5 gene, E2F-1 would also be switched o and thus cells in the suprabasal layer might not be inhibited in their passage through to terminal dierentiation. The data presented here has examined the role of E2F-1 in keratinocyte dierentiation in more detail, and we show that expression of E2F-1 in normal keratinocytes inhibits both induction of, and continued expression of dierentiation-speci®c genes in human keratinocytes. Whilst, it is accepted that the ®ndings reported herein result from overexpression studies. The relevance of this approach is supported by our ®ndings that epidermal squamous cell carcinomas overexpress E2F-1 in situ.
While overexpression of E2F-1 can override the events that normally regulate growth arrest and dierentiation in keratinocytes, the use of a dominant/negative E2F-1 construct leads to a decrease in transcription of E2F-dependent proliferation-associated genes in some epithelial cell lines. Inhibition of E2F-dependent promoters (cdc2 and E2F-1) could be achieved with a construct containing the DNA binding domain and dimerization domain of E2F-1. However, expression of the 116 ± 235 construct was not followed by an induction of dierentiation markers in normal keratinocytes. This ®nding is similar to that reported for keratinocytes overexpressing p16, p21 or p27 (Harvat et al., 1998) , or keratinocytes treated with TGF b or retinoic acid (Saunders et al., 1993a) . Combined, these data indicate that growth arrest mediated by suppression of the Rb pathway is not sucient to trigger keratinocyte dierentiation. However, overactivity of this pathway mediated by E2F-1 overexpression is able to suppress dierentiationspeci®c markers. This latter point may be relevant to the development of carcinomas in which keratinocytes overexpress E2F-1 and consequently may suppress the dierentiation pathway.
In contrast to the decreased expression from the promoters of the proliferation-associated genes cdc2 and E2F-1, E2F inhibitors induced keratin 14 promoter activity. The mechanism underlying this is unknown as the Keratin 14 promoter does not contain a known E2F response element. In one model (Zhang et al., 1999) , competitive inhibition of DNA binding did not lead to a decrease in cell proliferation and could override growth arrest induced by p16
INK4a
, TGFb or contact inhibition. The proposed mechanism for this is that the normal transcriptional repression by Rb-E2F complexes is lost. Therefore, one possibility is that upstream regulators of the keratin 14 gene (possibly regulated by Rb activity) are derepressed by the E2F inhibitor, allowing for an increase in keratin 14 promoter activity. Further studies are required to explore this issue.
One possibility raised by the present work is that of targeting E2F activity as a potential treatment for hyperproliferative skin disorders such as psoriasis or cancer. A number of strategies have been reported to successfully block either E2F-1 function or E2F DNA binding activity (Morishita et al., 1995; Ishizaki et al., 1996; Chiang et al., 1997 Chiang et al., , 1998 Bandara et al., 1997; Maeshima et al., 1998) , and each has been shown to inhibit cell growth. Some of these have been tested as potential therapies for tumours or hyperproliferative diseases with promising results. These data suggest that blocking E2F DNA binding may represent a further therapeutic approach to the treatment of skin disease.
Materials and methods

Cell culture
Primary human epidermal keratinocytes and SCC 25 cells were grown as previously described (Jones et al., 1997b) . HaCaT cells, an immortalised cell line spontaneously derived from the skin (Boukamp et al., 1988) , Cos 1 cells, a cell line derived from monkey kidney epithelium, and KJD-1/SV40 cells, a keratinocyte cell line produced by transforming normal keratinocytes with the SV40 virus (a generous gift from Dr Phillip Gallimore, Birmingham, UK), were grown in DMEM (CSL Ltd, Melbourne, Australia), supplemented with 10% (vol/vol ) fetal bovine serum (FBS; CSL), 10 000 U/ml penicillin/streptomycin (Life Technologies, Sydney, Australia) and 10 mg/ml gentamycin (David Bull Laboratories, Melbourne, Australia). Colo 16 cells, a cell line derived from a metastatic squamous cell carcinoma (Moore et al., 1975) were grown in RPMI 1640 (Commonwealth serum laboratories (CSL), Melbourne, Australia), supplemented with 10% (vol/vol) FBS, 10 000 U/ml penicillin/streptomycin and 10 mg/ml gentamycin.
Transfection of cells and reporter assays
A 949 bp fragment of the human cdc2 promoter directing expression of a CAT reporter gene (cdc2-CAT) was a generous gift from Dr Steven Dalton and has been described previously to be subject to transcriptional downregulation during squamous dierentiation . A 2.9 kb fragment of the Transglutaminase type 1 promoter linked to the ®re¯y luciferase gene (TG I-Luc) has previously been described (Saunders et al., 1993a) . We have previously shown that the 2.9 kb TG 1 promoter fragment is sucient to bestow dierentiation-speci®city to the CAT reporter gene in a transgenic mouse model (Medvedev et al., 1999) . A 180 bp fragment of the Keratin 14 promoter directing expression of a CAT reporter gene (K14-CAT) was produced and characterized as described (Hilditch-Maguire, 1998). The Keratin 10 reporter (K10-Luc) contains 1665 bp of 5' anking and untranslated sequence from the human cytokeratin 10 gene linked to ®re¯y luciferase (Rieger and Franke, 1988; Andersen et al., 1993) . The cytokeratin 10 promoter has been previously used to express transgenes in a dierentiation-speci®c manner in mice (Bailleul et al., 1990; Blessing et al., 1996) . The b actin-CAT reporter gene (Saunders et al., 1993a) or b actin-Luciferase reporter gene were used to normalize for transfection eciency. The CMV-E2F-1 plasmid was a generous gift from Dr K Helin. The CMV-GFP construct, containing green uorescent protein expressed from the CMV promoter was used as a control. The E2F DNA binding inhibitory constructs were produced by designing primers to the speci®ed regions of E2F-1, producing a PCR product using CMV-E2F 1 as a template, subcloning the PCR product into the pGEM-T vector (Promega, Sydney, Australia) then cloning the excised product into the VP22 mammalian expression system (Integrated Sciences, Brisbane, Australia) using standard techniques. The control construct (VP22-GFP) contained the green¯uorescent protein inserted into the same vector. Constructs were sequenced using`Big dye' terminator chemistry (Perkins Elmer) and standard protocols, then samples were run on a Perkins Elmer 377 sequence analyser. The numbers used to name the construct represent the E2F-1 amino acid number at the start and end of each construct. Oligonucleotides for the construction of E2F inhibitors (Life Technologies) were: 5'116 GGT ACC GAA TTC CAT GGG AAA AGG TGT GAA ATC C; 5' 181 GGT ACC GAA TTC CAT GGC CAA GAA GTC CAA GAA C; 3' 191 GGT ACC CTC GAG TCA GCC CAG CCA CTG GAT GTG; 3' 235 GGT ACC CTC GAG TCA GGA GAG CAG GCG CAG CTG.
Transient transfections of cells in 10 cm 2 well were performed when the cells were 50% con¯uent and assayed for reporter activity 48 h post-transfection. For keratinocytes, wells were rinsed once with minimal serum free medium (Life Technologies) then transfected with 1 mg of reporter, 0.3 mg of b actin, 0.3 mg of treatment (vector containing green uorescent protein as control, CMV-E2F 1 or VP22-116-235 as treatments) and 4 ml of Lipofectamine (Life Technologies). The lipofectamine and the individual plasmids were prepared seperately in 100 ml of minimal serum free medium each, mixed together then left for 30 min at room temperature. These solutions were mixed with 0.8 ml of minimal serum free medium per transfection and the diluted complexes added to the rinsed cells for 5 h at 378C, after which the cells were returned to complete serum free medium. SCC 25 cells were transfected by calcium phosphate whilst HaCat cells, KJD-1/SV40 cells, Colo 16 cells and Cos 1 cells were transfected with`Eectene' (Qiagen, Brisbane, Australia) using methods described by the manufacturer.
Chloramphenicol acetyltransferase assays were performed using a CAT ELISA kit (Roche, Brisbane, Australia) as per the manufacturer's instructions, while luciferase assays were performed as previously described (Saunders et al., 1993a; Dahler et al., 1998) . Data was analysed using the software analysis programme, PRISM (GraphPad, USA) and results were expressed relative to the activity in proliferating cells.
DNA synthesis assay and RT ± PCR
Cell proliferation rates were estimated by measuring the incorporation of tritiated thymidine into the cells as previously described (Saunders et al., 1993b; Saunders and Jetten, 1994) . Total RNA isolation and reverse transcriptasepolymerase chain reaction for E2F-1 and Transglutaminase type 1 expression was performed as previously described (Jones, et al., 1997b; Saunders et al., 1999) . Oligonucleotides for estimating the expression of transglutaminase type I (TG I) were; 5'TG I TGGAGGCAGAGGACGCGGTGA, 3'TG I GAGAGCTGTGGGCTGTCCAAG.
Statistical analysis
Comparison of putative E2F DNA binding inhibitors was assessed by the Mann ± Whitney U test and Student t test. Statistical signi®cance was accepted when P values were less than 0.05.
